

Massimiliano Mazzone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1832480/publications.pdf>

Version: 2024-02-01

149
papers

17,204
citations

22153

59
h-index

14759

127
g-index

156
all docs

156
docs citations

156
times ranked

24101
citing authors

#	ARTICLE	IF	CITATIONS
1	Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 126-141.	3.4	9
2	The c-MET receptor tyrosine kinase contributes to neutrophil-driven pathology in cutaneous leishmaniasis. <i>PLoS Pathogens</i> , 2022, 18, e1010247.	4.7	1
3	Repression of hypoxia-inducible factor-1 contributes to increased mitochondrial reactive oxygen species production in diabetes. <i>ELife</i> , 2022, 11, .	6.0	31
4	Iron supplementation is sufficient to rescue skeletal muscle mass and function in cancer cachexia. <i>EMBO Reports</i> , 2022, 23, e53746.	4.5	26
5	PHGDH heterogeneity potentiates cancer cell dissemination and metastasis. <i>Nature</i> , 2022, 605, 747-753.	27.8	77
6	Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix. <i>Nature Metabolism</i> , 2022, 4, 693-710.	11.9	49
7	A cannabidiol aminoquinone derivative activates the PP2A/B55 α /HIF pathway and shows protective effects in a murine model of traumatic brain injury. <i>Journal of Neuroinflammation</i> , 2022, 19, .	7.2	8
8	Metabolic traits ruling the specificity of the immune response in different cancer types. <i>Current Opinion in Biotechnology</i> , 2021, 68, 124-143.	6.6	4
9	Neutrophils Fuel Effective Immune Responses through Gluconeogenesis and Glycogenesis. <i>Cell Metabolism</i> , 2021, 33, 411-423.e4.	16.2	84
10	MicroRNA-Mediated Metabolic Shaping of the Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 127.	3.7	11
11	Differential Effects of Trp53 Alterations in Murine Colorectal Cancer. <i>Cancers</i> , 2021, 13, 808.	3.7	5
12	BNIP3 promotes HIF1 α -driven melanoma growth by curbing intracellular iron homeostasis. <i>EMBO Journal</i> , 2021, 40, e106214.	7.8	38
13	Hypoxia-induced miR-210 modulates the inflammatory response and fibrosis upon acute ischemia. <i>Cell Death and Disease</i> , 2021, 12, 435.	6.3	8
14	How metabolism bridges cytotoxic CD8+ T cells through epigenetic modifications. <i>Trends in Immunology</i> , 2021, 42, 401-417.	6.8	18
15	Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation. <i>Science Advances</i> , 2021, 7, .	10.3	26
16	Protein Phosphatase 2A Mediates YAP Activation in Endothelial Cells Upon VEGF Stimulation and Matrix Stiffness. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 675562.	3.7	15
17	Tumor vessel co-option probed by single-cell analysis. <i>Cell Reports</i> , 2021, 35, 109253.	6.4	44
18	Isolation and separation of murine tumor-associated macrophages (TAMs) subpopulations from orthotopic 4T1 breast tumors. <i>STAR Protocols</i> , 2021, 2, 100481.	1.2	2

#	ARTICLE	IF	CITATIONS
19	ESDN inhibits melanoma progression by blocking E-selectin expression in endothelial cells via STAT3. <i>Cancer Letters</i> , 2021, 510, 13-23.	7.2	4
20	Acetylaspartate release by glutaminolytic ovarian cancer cells sustains protumoral macrophages. <i>EMBO Reports</i> , 2021, 22, e51981.	4.5	22
21	Leptin brain entry via a tanycytic LepR-EGFR shuttle controls lipid metabolism and pancreas function. <i>Nature Metabolism</i> , 2021, 3, 1071-1090.	11.9	67
22	Betulinic Acid Hydroxamate is Neuroprotective and Induces Protein Phosphatase 2A-Dependent HIF-1 α Stabilization and Post-transcriptional Dephosphorylation of Prolyl Hydrolase 2. <i>Neurotherapeutics</i> , 2021, 18, 1849-1861.	4.4	9
23	IL1 β Promotes Immune Suppression in the Tumor Microenvironment Independent of the Inflammasome and Gasdermin D. <i>Cancer Immunology Research</i> , 2021, 9, 309-323.	3.4	48
24	Immunity, Hypoxia, and Metabolism—the Magic Triangle of Cancer: Implications for Immunotherapy. <i>Physiological Reviews</i> , 2020, 100, 1-102.	28.8	190
25	Targeting Neupilin-1 with Nanobodies Reduces Colorectal Carcinoma Development. <i>Cancers</i> , 2020, 12, 3582.	3.7	23
26	DNA methylation repels binding of hypoxia-inducible transcription factors to maintain tumor immunotolerance. <i>Genome Biology</i> , 2020, 21, 182.	8.8	39
27	Macrophage-derived glutamine boosts satellite cells and muscle regeneration. <i>Nature</i> , 2020, 587, 626-631.	27.8	119
28	Understanding Metal Dynamics Between Cancer Cells and Macrophages: Competition or Synergism?. <i>Frontiers in Oncology</i> , 2020, 10, 646.	2.8	26
29	B55 α /PP2A Limits Endothelial Cell Apoptosis During Vascular Remodeling. <i>Circulation Research</i> , 2020, 127, 707-723.	4.5	24
30	Neutrophilic HGF-MET Signalling Exacerbates Intestinal Inflammation. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1748-1758.	1.3	12
31	Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1673-1697.	4.2	38
32	Editorial: Macrophage Metabolism and Immune Responses. <i>Frontiers in Immunology</i> , 2020, 11, 1078.	4.8	4
33	An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates. <i>Cancer Cell</i> , 2020, 37, 21-36.e13.	16.8	253
34	Impact of Immunometabolism on Cancer Metastasis: A Focus on T Cells and Macrophages. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a037044.	6.2	10
35	Glufosinate constrains synchronous and metachronous metastasis by promoting anti-tumor macrophages. <i>EMBO Molecular Medicine</i> , 2020, 12, e11210.	6.9	29
36	PoEMs edit breast cancer outcome. <i>Aging</i> , 2020, 12, 4045-4047.	3.1	2

#	ARTICLE	IF	CITATIONS
37	Role and therapeutic potential of dietary ketone bodies in lymph vessel growth. <i>Nature Metabolism</i> , 2019, 1, 666-675.	11.9	45
38	Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer. <i>Cell Reports</i> , 2019, 28, 104-118.e8.	6.4	67
39	Blood Vessel Proximity Shapes Cancer Cell Metabolism. <i>Cell Metabolism</i> , 2019, 30, 16-18.	16.2	9
40	Podoplanin-Expressing Macrophages Promote Lymphangiogenesis and Lymphoinvasion in Breast Cancer. <i>Cell Metabolism</i> , 2019, 30, 917-936.e10.	16.2	150
41	Hypoxic cancer-associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling. <i>Science Signaling</i> , 2019, 12, .	3.6	83
42	Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. <i>Cancer Research</i> , 2019, 79, 4196-4210.	0.9	53
43	Tumor-associated macrophages: a short compendium. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 1447-1458.	5.4	71
44	Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2019, 79, 1938-1951.	0.9	58
45	Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis. <i>Annual Review of Physiology</i> , 2019, 81, 535-560.	13.1	44
46	Caspase-8 modulates physiological and pathological angiogenesis during retina development. <i>Journal of Clinical Investigation</i> , 2019, 129, 5092-5107.	8.2	16
47	Hypoxia Inducible Factor Activation Prevents Renal Mitochondria Dysfunction and Improves Cortical Oxygenation in Type 1 Diabetic Mice. <i>FASEB Journal</i> , 2019, 33, lb591.	0.5	0
48	Metabolism and <sc>TAM</sc> functions"it takes two to tango. <i>FEBS Journal</i> , 2018, 285, 700-716.	4.7	73
49	Is There Merit for MET-Targeted Therapies in Gastroesophageal Cancer?. <i>JAMA Oncology</i> , 2018, 4, 131.	7.1	1
50	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. <i>Nature Communications</i> , 2018, 9, 4112.	12.8	55
51	Neutrophils enhance early <i>Trypanosoma brucei</i> infection onset. <i>Scientific Reports</i> , 2018, 8, 11203.	3.3	33
52	Quiescent Endothelial Cells Upregulate Fatty Acid β -Oxidation for Vasculoprotection via Redox Homeostasis. <i>Cell Metabolism</i> , 2018, 28, 881-894.e13.	16.2	174
53	Impairment of Angiogenesis by Fatty Acid Synthase Inhibition Involves mTOR Malonylation. <i>Cell Metabolism</i> , 2018, 28, 866-880.e15.	16.2	154
54	The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 107-116.	9.6	57

#	ARTICLE	IF	CITATIONS
55	<i>SLC25A26</i> overexpression impairs cell function via mtDNA hypermethylation and rewiring of methyl metabolism. <i>FEBS Journal</i> , 2017, 284, 967-984.	4.7	33
56	The mTOR and PP2A Pathways Regulate PHD2 Phosphorylation to Fine-Tune HIF1 α Levels and Colorectal Cancer Cell Survival under Hypoxia. <i>Cell Reports</i> , 2017, 18, 1699-1712.	6.4	88
57	Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. <i>Nature Communications</i> , 2017, 8, 14206.	12.8	81
58	Hypoxia determines survival outcomes of bacterial infection through HIF-1 α -dependent reprogramming of leukocyte metabolism. <i>Science Immunology</i> , 2017, 2, .	11.9	61
59	PHD2 Targeting Overcomes Breast Cancer Cell Death upon Glucose Starvation in a PP2A/B55 α -Mediated Manner. <i>Cell Reports</i> , 2017, 18, 2836-2844.	6.4	24
60	MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability. <i>Molecular Cancer</i> , 2017, 16, 55.	19.2	12
61	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. <i>Immunity</i> , 2017, 47, 789-802.e9.	14.3	207
62	Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth. <i>EMBO Molecular Medicine</i> , 2017, 9, 1629-1645.	6.9	54
63	Retinoid X receptor suppresses a metastasis-promoting transcriptional program in myeloid cells via a ligand-insensitive mechanism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10725-10730.	7.1	24
64	α -ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. <i>Nature Immunology</i> , 2017, 18, 985-994.	14.5	715
65	Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis. <i>Cell Reports</i> , 2017, 20, 1654-1666.	6.4	258
66	Loss of Caveolin-1 in Metastasis-Associated Macrophages Drives Lung Metastatic Growth through Increased Angiogenesis. <i>Cell Reports</i> , 2017, 21, 2842-2854.	6.4	46
67	Tumor matrix stiffness promotes metastatic cancer cell interaction with the endothelium. <i>EMBO Journal</i> , 2017, 36, 2373-2389.	7.8	144
68	Blockade of Glutamine Synthetase Enhances Inflammatory Response in Microglial Cells. <i>Antioxidants and Redox Signaling</i> , 2017, 26, 351-363.	5.4	61
69	Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis. <i>Oncotarget</i> , 2017, 8, 93688-93703.	1.8	7
70	Prolyl hydroxylase 2 inactivation enhances glycogen storage and promotes excessive neutrophilic responses. <i>Journal of Clinical Investigation</i> , 2017, 127, 3407-3420.	8.2	71
71	MIF-Mediated Hemodilution Promotes Pathogenic Anemia in Experimental African Trypanosomosis. <i>PLoS Pathogens</i> , 2016, 12, e1005862.	4.7	20
72	The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. <i>Nature Communications</i> , 2016, 7, 13720.	12.8	217

#	ARTICLE	IF	CITATIONS
73	Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia. <i>European Heart Journal</i> , 2016, 37, 2993-2997.	2.2	40
74	Tumour hypoxia causes DNA hypermethylation by reducing TET activity. <i>Nature</i> , 2016, 537, 63-68.	27.8	521
75	FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. <i>Scientific Reports</i> , 2016, 6, 33453.	3.3	168
76	Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis. <i>Cell Metabolism</i> , 2016, 24, 701-715.	16.2	352
77	Vessel Normalization in the Spot-LIGHT of Cancer Treatment. <i>Trends in Molecular Medicine</i> , 2016, 22, 85-87.	6.7	4
78	Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer. <i>Gut</i> , 2016, 65, 990-1000.	12.1	67
79	The impact of hypoxia on tumor-associated macrophages. <i>Journal of Clinical Investigation</i> , 2016, 126, 3672-3679.	8.2	401
80	PHD1 regulates p53-mediated colorectal cancer chemoresistance. <i>EMBO Molecular Medicine</i> , 2015, 7, 1350-1365.	6.9	43
81	Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma. <i>Oncotarget</i> , 2015, 6, 36418-36425.	1.8	40
82	Semaphorin7A regulates neuroglial plasticity in the adult hypothalamic median eminence. <i>Nature Communications</i> , 2015, 6, 6385.	12.8	105
83	MET is required for the recruitment of anti-tumoural neutrophils. <i>Nature</i> , 2015, 522, 349-353.	27.8	359
84	The Cancer Cell Oxygen Sensor PHD2 Promotes Metastasis via Activation of Cancer-Associated Fibroblasts. <i>Cell Reports</i> , 2015, 12, 992-1005.	6.4	66
85	Factor-inhibiting HIF1 (FIH1) is required for human vascular endothelial cell survival. <i>FASEB Journal</i> , 2015, 29, 2814-2827.	0.5	27
86	Identification of a chronic non-neurodegenerative microglia activation state in a mouse model of peroxisomal α -oxidation deficiency. <i>Glia</i> , 2015, 63, 1606-1620.	4.9	45
87	Functional MMP10 is required for efficient tissue repair after experimental hind limb ischemia. <i>FASEB Journal</i> , 2015, 29, 960-972.	0.5	19
88	Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation. <i>Oncotarget</i> , 2015, 6, 11295-11309.	1.8	30
89	Sixty shades of oxygen-an attractive opportunity for cancer immunotherapy. <i>Annals of Translational Medicine</i> , 2015, 3, 187.	1.7	2
90	Oxygen Signaling in Physiological and Pathological Angiogenesis. , 2015, , 329-349.		0

#	ARTICLE	IF	CITATIONS
91	Prolyl hydroxylase domain 1 (PHD1) to mediate chemoresistance in colorectal cancer.. Journal of Clinical Oncology, 2015, 33, e14534-e14534.	1.6	0
92	Immune response triggered by a novel molecular crosstalk of major hallmarks of cancer: Angiogenesis, mismatch repair, and immune pathways.. Journal of Clinical Oncology, 2015, 33, 11054-11054.	1.6	1
93	The Anti-Proliferative Effect of L-Carnosine Correlates with a Decreased Expression of Hypoxia Inducible Factor 1 alpha in Human Colon Cancer Cells. PLoS ONE, 2014, 9, e96755.	2.5	51
94	Brain Endothelial Cells Control Fertility through Ovarian-Steroidâ€œDependent Release of Semaphorin 3A. PLoS Biology, 2014, 12, e1001808.	5.6	56
95	The Fragile X Protein binds mRNA s involved in cancer progression and modulates metastasis formation. EMBO Molecular Medicine, 2014, 6, 567-568.	6.9	0
96	Altering the intratumoral localization of macrophages to inhibit cancer progression. Onc Immunology, 2014, 3, e27872.	4.6	9
97	Tumor Hypoxia Does Not Drive Differentiation of Tumor-Associated Macrophages but Rather Fine-Tunes the M2-like Macrophage Population. Cancer Research, 2014, 74, 24-30.	0.9	348
98	Endothelial deficiency of L1 reduces tumor angiogenesis and promotes vessel normalization. Journal of Clinical Investigation, 2014, 124, 4335-4350.	8.2	46
99	Histidine-Rich Glycoprotein Uptake and Turnover Is Mediated by Mononuclear Phagocytes. PLoS ONE, 2014, 9, e107483.	2.5	17
100	Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer. Oncotarget, 2014, 5, 12978-12989.	1.8	34
101	Endothelial Cell Reactions to Oxygen: Implications for Cancer. , 2014, , 267-282.		0
102	Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor Immunity. Cancer Cell, 2013, 24, 695-709.	16.8	505
103	Tanycytic VEGF-A Boosts Blood-Hypothalamus Barrier Plasticity and Access of Metabolic Signals to the Arcuate Nucleus in Response to Fasting. Cell Metabolism, 2013, 17, 607-617.	16.2	285
104	Inhibition of Tumor Angiogenesis and Growth by a Small-Molecule Multi-FGF Receptor Blocker with Allosteric Properties. Cancer Cell, 2013, 23, 477-488.	16.8	138
105	Renal CD133+/CD73+ Progenitors Produce Erythropoietin under Hypoxia and Prolyl Hydroxylase Inhibition. Journal of the American Society of Nephrology: JASN, 2013, 24, 1234-1241.	6.1	21
106	The Fragile X Protein binds m <scp>RNA</scp> s involved in cancer progression and modulates metastasis formation. EMBO Molecular Medicine, 2013, 5, 1523-1536.	6.9	106
107	PHD2 regulates arteriogenic macrophages through TIE2 signalling. EMBO Molecular Medicine, 2013, 5, 843-857.	6.9	40
108	The â€œcord of lifeâ€œ-serving antiangiogenic therapy. Blood, 2013, 121, 4254-4255.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Overcoming Resistance to Antiangiogenic Therapies. <i>Oncologist</i> , 2012, 17, 1039-1050.	3.7	53
110	Genetic Deficiency in Plasma Protein HRG Enhances Tumor Growth and Metastasis by Exacerbating Immune Escape and Vessel Abnormalization. <i>Cancer Research</i> , 2012, 72, 1953-1963.	0.9	32
111	VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AVITA and AVOREN randomised trials. <i>Lancet Oncology</i> , The, 2012, 13, 724-733.	10.7	174
112	Loss of the Oxygen Sensor PHD3 Enhances the Innate Immune Response to Abdominal Sepsis. <i>Journal of Immunology</i> , 2012, 189, 1955-1965.	0.8	70
113	miR-511-3p Modulates Genetic Programs of Tumor-Associated Macrophages. <i>Cell Reports</i> , 2012, 1, 141-154.	6.4	193
114	Gene-Targeting of Phd2 Improves Tumor Response to Chemotherapy and Prevents Side-Toxicity. <i>Cancer Cell</i> , 2012, 22, 263-277.	16.8	117
115	Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform. <i>EMBO Molecular Medicine</i> , 2012, 4, 234-250.	6.9	82
116	Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. <i>Nature</i> , 2011, 479, 122-126.	27.8	265
117	Semaphorin Signals on the Road of Endothelial Tip Cells. <i>Developmental Cell</i> , 2011, 21, 189-190.	7.0	24
118	Growing tumor vessels: More than one way to skin a cat – Implications for angiogenesis targeted cancer therapies. <i>Molecular Aspects of Medicine</i> , 2011, 32, 71-87.	6.4	92
119	HRG Inhibits Tumor Growth and Metastasis by Inducing Macrophage Polarization and Vessel Normalization through Downregulation of PlGF. <i>Cancer Cell</i> , 2011, 19, 31-44.	16.8	628
120	Systemic and Targeted Delivery of Semaphorin 3A Inhibits Tumor Angiogenesis and Progression in Mouse Tumor Models. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 741-749.	2.4	105
121	Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 393-404.	27.6	252
122	Sema3E – Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 2945-2945.	8.2	0
123	Role of Delta-like-4/Notch in the Formation and Wiring of the Lymphatic Network in Zebrafish. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1695-1702.	2.4	118
124	Impaired Autonomic Regulation of Resistance Arteries in Mice With Low Vascular Endothelial Growth Factor or Upon Vascular Endothelial Growth Factor Trap Delivery. <i>Circulation</i> , 2010, 122, 273-281.	1.6	37
125	Anti-Placental Growth Factor Reduces Bone Metastasis by Blocking Tumor Cell Engraftment and Osteoclast Differentiation. <i>Cancer Research</i> , 2010, 70, 6537-6547.	0.9	47
126	Loss or Silencing of the PHD1 Prolyl Hydroxylase Protects Livers of Mice Against Ischemia/Reperfusion Injury. <i>Gastroenterology</i> , 2010, 138, 1143-1154.e2.	1.3	108

#	ARTICLE	IF	CITATIONS
127	Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease. <i>Cell</i> , 2010, 141, 178-190.	28.9	243
128	Sema3Eâ€Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. <i>Journal of Clinical Investigation</i> , 2010, 120, 2684-2698.	8.2	157
129	Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited. <i>Cancer Cell</i> , 2009, 15, 167-170.	16.8	360
130	Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 315-326.	27.6	195
131	Role and Therapeutic Potential of VEGF in the Nervous System. <i>Physiological Reviews</i> , 2009, 89, 607-648.	28.8	385
132	Regulation of Angiogenesis by Oxygen and Metabolism. <i>Developmental Cell</i> , 2009, 16, 167-179.	7.0	361
133	Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization. <i>Cell</i> , 2009, 136, 839-851.	28.9	727
134	Metron factor-1 prevents liver injury without promoting tumor growth and metastasis. <i>Hepatology</i> , 2008, 47, 2010-2025.	7.3	15
135	A lifeline for suffocating tissues. <i>Nature</i> , 2008, 453, 1194-1195.	27.8	19
136	Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. <i>Nature Genetics</i> , 2008, 40, 170-180.	21.4	433
137	FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. <i>Nature Reviews Cancer</i> , 2008, 8, 942-956.	28.4	504
138	â€œActiveâ€Cancer Immunotherapy by Anti-Met Antibody Gene Transfer. <i>Cancer Research</i> , 2008, 68, 9176-9183.	0.9	36
139	The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. <i>Journal of Experimental Medicine</i> , 2008, 205, 1155-1171.	8.5	87
140	Genetic targeting of the kinase activity of the Met receptor in cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 11412-11417.	7.1	38
141	The Therapeutic Potential of Hepatocyte Growth Factor to Sensitize Ovarian Cancer Cells to Cisplatin and Paclitaxel In vivo. <i>Clinical Cancer Research</i> , 2007, 13, 2191-2198.	7.0	29
142	Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels. <i>Cell</i> , 2007, 131, 463-475.	28.9	722
143	Building in resistance to endothelial cell death. <i>Nature Genetics</i> , 2007, 39, 1308-1309.	21.4	3
144	Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 5090-5095.	7.1	147

#	ARTICLE	IF	CITATIONS
145	The Met pathway: master switch and drug target in cancer progression. FASEB Journal, 2006, 20, 1611-1621.	0.5	117
146	Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell, 2004, 6, 61-73.	16.8	282
147	An uncleavable form of pro- α scatter factor suppresses tumor growth and dissemination in mice. Journal of Clinical Investigation, 2004, 114, 1418-1432.	8.2	85
148	Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell, 2003, 3, 347-361.	16.8	1,244
149	An HGF α -MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. Nature Biotechnology, 2002, 20, 488-495.	17.5	22